Besides, repeated TACE treatment would aggravate liver function and induce local ischemia and hypoxia environment, resulting in increased expression of the hypoxia-inducible factor and vascular endothelial growth factor in HCC and eventually leading to tumor recurrence. Here, VEGFA is linked to hepatocellular carcinoma.